Also known as: CMT, hereditary motor sensory neuropathy, HMSN
Usually manifests in childhood or early adulthood, though some forms present later. Affects males and females equally. Multiple genetic forms with varying inheritance patterns (autosomal dominant, recessive, or X-linked).
Clinical trials for CMT are evaluating therapies targeting specific CMT genetic subtypes, including those for CMT1A (PMP22 overexpression), CMT1B, and CMT2A mutations. Antisense oligonucleotides and gene therapy approaches are in development. The Charcot-Marie-Tooth Association provides comprehensive trial information and patient support. Genetic testing to identify the specific CMT subtype is important, as several emerging therapies target specific mutations. Therapies like PMP22-targeting antisense oligonucleotides show promise for CMT1A. Regular neurological monitoring, physical therapy, and appropriate assistive devices (braces, walkers) can slow functional decline and improve quality of life.
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...